Invention and Early History of Exon Skipping and Splice Modulation
Authors:
- 1 September 2018
- book chapter
- Published by Springer Nature
- Vol. 1828, 3-30
Abstract
Since its discovery in 1977, much has been known about RNA splicing and how it plays a central role in human development, function, and, notably, disease. Defects in RNA splicing account for at least 10% of all genetic disorders, with the number expected to increase as more information is uncovered on the contribution of noncoding genomic regions to disease. Splice modulation through the use of antisense oligonucleotides (AOs) has emerged as a promising avenue for the treatment of these disorders. In fact, two splice-switching AOs have recently obtained approval from the US Food and Drug Administration: eteplirsen (Exondys 51) for Duchenne muscular dystrophy, and nusinersen (Spinraza) for spinal muscular atrophy. These work by exon skipping and exon inclusion, respectively. In this chapter, we discuss the early development of AO-based splice modulation therapy—its invention, first applications, and its evolution into the approach we are now familiar with. We give a more extensive history of exon skipping in particular, as it is the splice modulation approach given the most focus in this book. Key words Pre-mRNA splicing Antisense therapy Exon skipping/inclusion Antisense history Antisense oligonucleotides Cryptic splice correction Isoform switching Exon inclusion Golodirsen (SRP-4053) NS-065/NCNP-01Keywords
This publication has 125 references indexed in Scilit:
- The significant other: splicing by the minor spliceosomeWIREs RNA, 2012
- An integrated encyclopedia of DNA elements in the human genomeNature, 2012
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Mechanisms of alternative splicing regulation: insights from molecular and genomics approachesNature Reviews Molecular Cell Biology, 2009
- Biological Barriers to Therapy with Antisense and siRNA OligonucleotidesMolecular Pharmaceutics, 2009
- Alternative isoform regulation in human tissue transcriptomesNature, 2008
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceThe American Journal of Human Genetics, 2008
- Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotidesHuman Mutation, 2006
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cellsGene Therapy, 2004